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There have been dramatic improvements in our ability to more accurately diagnose the underlying genetic causes
of developmental delay/intellectual disability; however, there is less known about the treatment trajectory and
whether or not patient management and outcomes have changed due to the information gained from genetic
testing. Here we report a case study of a 20-month-old male first referred to the genetics clinic in 2008 for
interhemispheric cysts, agenesis of the corpus callosum, left cortical dysplasia, and developmental delay of unknown
etiology. The diagnostic work-up for this patient included chromosomal microarray which detected >20% mosaicism
for monosomy 7, which raised concern for a possible myelodysplastic syndrome. The clone was not detected in
stimulated peripheral blood cultures and his karyotype was reported as a normal male. Because of this microarray
finding, he was referred to pediatric hematology/oncology where he was confirmed to have a pre-symptomatic
diagnosis of myelodysplastic syndrome and was treated with chemotherapy and a bone-marrow transplant. This case
illustrates the clinical utility of microarray testing and the importance of long-term follow-up to assess patient
outcomes.
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Over the past ten years, a dramatic shift in clinical labora-
tory testing has taken place in the assessment of patients
with suspected genetic abnormalities related to develop-
mental delay/intellectual disability, congenital anomalies,
and dysmorphic features from low resolution techniques
to high resolution genomic technologies.
Traditionally, karyotyping and fluorescence in situ
hybridization (FISH) were the methods used for cytogenetic
analysis. Karyotyping can detect aberrations at a resolution
averaging 5–10 megabases while FISH, a more sensitive
technique, enables visualization of targeted chromosomal
regions at a resolution of greater than or equal to 150 kilo-
bases. However, FISH is limited in its application by the
probes used to detect a specific genetic locus. For this rea-
son, karyotyping and FISH have been commonly used in* Correspondence: alka@ggc.org
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unless otherwise stated.tandem in clinical practice (karyotyping to visualize the
whole genome and FISH to target specific locations at a
higher resolution) in order to improve diagnostic yield.
Over the past decade, microarray technology has tran-
sitioned from the research laboratory to the clinical
laboratory and is used for assessing copy number varia-
tions (CNVs) in patients undergoing diagnostic testing
for developmental delay/intellectual disability due to its
ability to assess DNA copy number across the entire
genome at a resolution not possible with karyotype or
FISH [1]. Furthermore, the American College of Medical
Genetics and Genomics (ACMG) Practice Guidelines
published in 2011 and revised in 2013 recommend that
genomic microarrays be used as first-tier tests for the
postnatal evaluation of individuals with developmental
delay/intellectual disability [2,3]. However, current la-
boratory practices for chromosomal testing vary and
can range from a microarray as the sole diagnostic test
of choice, to a combination of several methods (e.g.l Ltd. This is an Open Access article distributed under the terms of the Creative
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polymerase chain reaction based methods) [4,5].
There are many reports in the scientific literature about
the increase in diagnostic yield by employing microarray
technology [1]. However, there is less information about
how this improved diagnostic yield translates into better
clinical outcomes. The current case serves as an example
of this enhanced patient outcome made possible by
chromosomal microarray. Secondly, this also highlights
that improvements in diagnostic yield are not limited only
to increased resolution but also allow for the detection of
chromosome abnormalities in non-dividing cells.
Case presentation
A prenatal ultrasound at 22 weeks gestation revealed
agenesis of the corpus callosum, suspected interhemi-
spheric cysts, and cortical dysplasia for the male patient.
There were no other complications or exposures during
the pregnancy. The delivery was normal. The birth weight
was 3,976 grams (75-90th percentile), the birth length was
53.5 cm (75-90th percentile), and the birth head circumfe-
rence was 36.5 cm (75-90th percentile). He was noted to
be irritable at birth, but was otherwise well. The child’s
parents are both healthy. The mother previously had a
miscarriage at 12 weeks. The child has 1 healthy brother.
A brain MRI at 5 days old confirmed agenesis of the
corpus callosum, two expanding interhemispheric cysts,
and left focal cortical dysplasia (Figure 1). At 1 month of
age, the patient underwent a left parietal craniotomy and
fenestration of the interhemispheric cysts. Post-surgery,
a pediatric head ultrasound revealed possible postopera-
tive hematoma. At 2 months of age, a head ultrasound
revealed a slight decrease in size of the multiloculated
midline cysts and a cystic change within the parasagittalFigure 1 Sagittal T1 image at 5 days old demonstrating
interhemispheric cysts and agenesis of corpus callosum.intraparenchymal hematoma compatible with encepha-
lomalacia. A brain MRI at 7 months confirmed the
presence of two interhemispheric cysts and agenesis of
the corpus callosum along with left frontal encephalo-
malacia and left frontal cortical dysplasia. The patient
underwent another craniotomy and fenestration of the
re-accumulated cysts at 8 months. He developed aseptic
meningitis following surgery. At 13 months of age, the
patient received a shunt for decompression of the inter-
hemispheric cysts with good results. The patient had de-
veloped right hemiparesis which improved after the
shunt placement.
The patient had a number of normal abdominal ultra-
sounds. He had chronic ear infections and received PE
tubes at 16 months old. Developmentally, the patient sat
at 6–7 months and walked at 19 months. He was re-
ferred to speech therapy due to concerns about speech
delay.
The patient was first referred to the genetics clinic at
20 months of age due to the previously described brain
abnormalities and developmental delay of unknown eti-
ology. He had a length of 80.5 cm (10th to 25th percent-
ile), a weight of 14.1 kg (90th-95th percentile) and a head
circumference of 50.3 cm (95th percentile). He was alert
and interactive. He periodically pointed and grunted. He
said “mama” and “dada” nonspecifically. He had slightly
down-slanting palpebral fissures with full eyebrows,
mildly increased tone on the ride side, and a wide-based,
unsteady gait (Figure 2).
Materials and methods
In order to provide an explanation for his clinical fea-
tures, high-resolution chromosome analysis (karyotype)
and chromosomal microarray analysis were requested.
Chromosomal microarray analysis was performed on 4
platforms using the 105 K Syndrome Plus (Oxford Gene
Technology, UK), Genome-wide SNP 6.0 microarray,
CytoScan HD array and CytoScan Dx Assay (Affymetrix,
Inc. USA, Figure 3) as per manufacturers’ instructions.
Results
Chromosome analysis revealed a normal, 46,XY karyo-
type. Initially, neither microarray nor MLPA subtelomere
analysis could be performed on the original blood sam-
ples (taken at birth) due to DNA degradation.
When the patient was 2 years old, microarray analysis
was repeated and revealed mosaicism (>20%) for mono-
somy 7 (Figure 3). FISH analyses were performed on
both the unstimulated and stimulated cultures on inter-
phase cells using the CEP 7 (D7Z1) Alpha Satellite Probe
specific for 7p11.1-q11.1 (Vysis #32-130007). Mosaic
monosomy 7 was identified in only 37 of 714 cells (~5%)
in the stimulated cultures and 21 of 100 (~21%) cells in
the unstimulated cultures (Figure 4). An attempt was
Figure 2 Facial features at 20 months old demonstrating
down-slanting palpebral fissures with full eyebrows.
Figure 3 Chromosomal microarray analysis showing mosaic monosom
(non-polymorphic probes) shows the mosaic loss represented as the line b
(SNP probes) also confirm the copy number probes and reflect the ~50% m
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cell pellet (from which the karyotypes were obtained)
but failed to identify any metaphases with monosomy 7
which most likely indicates the subpopulation of cells
stimulated by PHA does not contain −7 cells.
Monosomy 7 mosaicism has been causally linked to
gain of function mutations in RAS pathway genes [6].
As a result, clinical sequencing of the RAS pathway
genes PTPN11, SOS1, RAF1, and KRAS was completed
and all results were normal.
Monosomy 7 mosaicism was not felt to be the ex-
planation for the patient’s clinical features; however,
due to reports of an association between monosomy 7
mosaicism and myelodysplasia, the patient was re-
ferred to a pediatric hematologist/oncologist for fur-
ther evaluation. The patient had a bone marrow biopsy
which revealed evidence of myelodysplasia. He subse-
quently had chemotherapy and a bone marrow trans-
plant at 4 years old.
Almost one year after surgery, he was seen at the gen-
etics clinic for a follow-up visit. It was noted that several
follow-up bone marrow biopsies indicated normal bone
marrow without evidence of myelodysplasia. Chromo-
some analysis and FISH for monosomy 7 were normal
following the bone marrow transplant. The patient was
doing well with no subsequent issues and was not taking
any medications. He had a number of dental cavities at-
tributed to the use of chemotherapy but was makingy 7 using the CytoScan Dx Assay. The smooth signal plot
etween copy states 1 and 2. The four tracks on the allele plots
osaic loss of chromosome 7.
Figure 4 Fluorescence in situ hybridization using the CEP 7
probe performed on the direct peripheral blood specimen of
the proband showing normal (2 green signals) and abnormal
(1 green signal) interphase nuclei.
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right hand and right leg and preferred to use his left
hand.
Discussion
Monosomy 7 is one of the most frequent chromosomal ab-
normalities observed in myelodysplasia and acute myeloge-
nous leukemia (AML) [7,8]. Other congenital bone marrow
disorders, such as Fanconi anemia, congenital neutropenia
and familial monosomy 7, predispose to leukemia usually
through a myelodysplastic phase [5,9-11]. Early detection
and identification of monosomy 7 by microarray may allow
for earlier diagnosis and intervention which may translate
into improved patient prognosis.
We report the detection of monosomy 7 mosaicism in a
child referred for genetic testing due to mild developmental
delay, agenesis of the corpus callosum, interhemispheric
cysts, and left cortical dysplasia. The percent mosaicism for
monosomy 7 was readily detected and quantified by micro-
array and FISH analysis but not by high resolution chromo-
some analysis.
Monosomy 7 mosaicism was not felt to be the explan-
ation for his presenting clinical features. Neither did he
have symptoms, such as easy bruising or petechiae that
would suggest an underlying diagnosis of myelodyspla-
sia. Due to the association of monosomy 7 mosaicism
with myelodysplasia, he was referred to hematology/on-
cology and confirmed to have myelodysplasia based on
bone marrow biopsy. He subsequently had a bone mar-
row transplant with apparently curative outcome.Monosomy 7 is considered a poor prognostic sign in
individuals with myelodysplasia [10]. However, the early
detection of monosomy 7 prior to the development of
any related hematologic symptoms is believed to have
improved our patient’s long-term prognosis. If micro-
array had not detected monosomy 7 mosaicism during
his evaluation for other unrelated clinical features, the
diagnosis of myelodysplasia and subsequent bone mar-
row transplant would likely have been significantly de-
layed, resulting in a worse prognosis for our patient.
Given the lack of correlation of the level of mosaicism
and myelodysplaisa, any level of mosaicism for mono-
somy 7 would warrant further hematological evaluation
for possible myelodysplasia.
Conclusion
In conclusion, we believe that the fortuitous identifica-
tion of monosomy 7 mosaicism by microarray signifi-
cantly improved the clinical outcome for our patient.
The microarray result led to a referral to hematology/
oncology which would not have otherwise happened
until he developed symptoms of a hematologic disorder.
This demonstrates the benefits of multi-disciplinary col-
laboration when a significant microarray result is identi-
fied as having a potential impact on the management of
a patient.
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